资源描述:
《曲安奈德球周注射联合激光光凝治疗糖尿病视网膜病变黄斑水肿疗效观察.doc》由会员上传分享,免费在线阅读,更多相关内容在工程资料-天天文库。
1、曲安奈德球周注射联合激光光凝治疗糖尿病视网膜病变黄斑水肿疗效观察[摘耍]目的分析探讨曲安奈徳球周注射联合激光光凝治疗糖尿病视网膜病变黄斑水肿的疗效。方法把100例糖尿病视网膜病变黄斑水肿患者作为研究对象,这100例患者均为该院收治,收治时间在2014年5月12H-2015年5月12日期间,随机将这100例患者分成2组,实验组和对照组各50例,对照组采取激光光凝治疗,实验组采取曲安奈德球周注射联合激光光凝治疗,并在治疗结束后,对比分析两组的黄斑区视网膜厚度、眼压。结果实验组经治疗后的黄斑区视网膜厚度为(154.06土10.36)um,对照组经治疗后的黄斑区视网膜厚度为(201.35±10.94)
2、um(P<0.05);实验组经治疗后的眼压水平低于对照组,差异有统计学意义(P<0.05)o结论曲安奈德球周注射联合激光光凝治疗糖尿病视网膜病变黄斑水肿具有显著的疗效,可有效减少黄斑区视网膜厚度,改善患者的眼压情况,值得在临床实践中应用和推广。[关键词]曲安奈徳;激光光凝;糖尿病视网膜病变;黄斑水肿[中图分类号]R587.1[文献标识码]A[文章编号]1672-4062(2016)06(b)-0003-02WeekofTriamcinoloneAcetonideBallJointInjectionLaserPhotocoagulationTreatmentforDiabeticRetinopa
3、thySONGMing-mingJiamusicentralhospitalofophthalmology,Jiamusi,HeilongjiangProvince,154000China[Abstract]ObjectiveAnalysistostudytheweekoftriamcinoloneacetonidebal1jointinjectionlaserphotocoagulationtreatmentthecurativeeffectofdiabeticretinopathy,macu1aredema.MethodsThe100patientswithdiabeticretinopa
4、thy,macularedemaastheresearchobject,the100patientsofourhospital,were12solsticetimeinMay2014onMay12,2015,the100patientsweredividedinto2groupsatrandom,theexperimentalgroupandcontrolgroup,50casesinthecontrolgrouptreatedwithlaserphotocoagulation,experimentalgroupadoptinjectiontriamcinoloneacetonideballw
5、eekswithlaserphotocoagulationtherapy,andafterthetreatment,comparedtwogroupsofmacularretinalthicknessandintraocularpressure.ResultsTheexperimentalgroupaftertreatmentinthemacularareaforretinalthickness(154.06+10.36)um,thecontrolgroupaftertreatmentinthemacularareaofretinalthicknessforum(201.35+10.94)(P
6、<0.05);Theexperimentalgroupaftertreatmentofintraocularpressure1evelis1owerthanthecontrolgroup(P<0.05),thedifferenceisstatisticallysignificant.ConclusionTriamcinoloneacetonideinjectionjointballweekslaserphotocoagulationtreatmentofdiabeticretinopathy,macularedemahassignificantcurativeeffect,caneffecti
7、velyreducethemaculararearetinalthickness,improvepatientswithintraocularpressure,isworthyofapplicationandpopularizationinclinicalpractice.[Keywords]Triamcinoloneacetonide;Laserphotocoagulation;Diabetic